Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-DM1 (SRP-1003) in Type 1 Myotonic Dystrophy
NCT06138743Phase 2Enrolling by invitation
- Sponsor
- Sarepta Therapeutics
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 11
01
Overview
A Phase 2 trial of SRP-1003 in myotonic dystrophy type 1 (DM1), sponsored by Sarepta Therapeutics. Started Mar 2024; status: enrolling by invitation.
02
Drugs
SRP-1003
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT06138743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138743.